Abstract:Objective To prepare a conjugate vaccine by linking Haemophilus influenzae type b (Hib)polysaccharide to PsaA protein carrier and evaluate the immunogenicity and efficacy of the conjugate vaccine. Methods A recombinant protein rPsaA,expressed by using the genetic engineering technology, was used as a protein carrier to prepare conjugate vaccine together with Hib polysaccharide. Ten mice at age of 3 weeks were immunized with the conjugate vaccine,while another 10 age-matched mice were immunized with Hib-tetanus toxoid(Hib-TT)vaccine which was produced formerly as a control. The mice treated with equal volume of PBS were set up as the negative control. The IgG antibodies in serum samples against PsaA and Hib polysaccharide were detected in two weeks after the final immunization. A suspension of Pneumococ-cus was injected into the middle ears of mice from experiment and control group. Histopathological analysis was performed to measure the clearance of bacteria in the middle ears and the severity of infection on days 3 and 7 after bacterial challenge. Results The rPsaA protein was prepared by the genetic engineering tech-nology and purified successfully with anion-exchange column. The Hib polysaccharide-PsaA protein conju-gate vaccine was prepared through a series of amide condensation reactions. The detection of IgG antibodies against PsaA protein and Hib polysaccharide in the immunized mice demonstrated that there was no signifi-cant difference with the titer of IgG against Hib polysaccharide between the mice immunized with the Hib-PsaA conjugate vaccine and those immunized with the Hib-TT vaccine. Less Pneumococcus strains were de-tected in the middle ears of mice immunized with the conjugate vaccine than those mice immunized with the Hib-TT vaccine three days after challenge. The mice from control group showed severe inflammation in the middle ears than those from experiment group. The Hib polysaccharide-PsaA protein conjugate vaccine im-proved protection against Pneumococcus infections as compared with the Hib-TT vaccine. Conclusion The rPsaA protein could be produced by genetic engineering technology and purified by anion-exchange column. The Hib polysaccharide was successfully conjugated with the rPsaA protein through amide condensation reac-tion. Both anti-PsaA and anti-Hib immune responses were induced in young mice by the injection of Hib pol-ysaccharide-PsaA protein conjugate vaccine. Apart from providing protection against Hib infection,the con-jugate vaccine might also be used for the prevention of acute otitis media caused by Pneumococcus infection.

Analysis of Immune Effect on Streptococcus suis-Haemophilus parasuis Bivalent Subunit Vaccine in Mice

Combined Immunoinformatics to Design and Evaluate a Multi-Epitope Vaccine Candidate against Streptococcus suis Infection

TLR4 Agonist Combined with Trivalent Protein JointS of <i>Streptococcus suis</i> Provides Immunological Protection in Animals

A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis

Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2

Development of a Universal Multi-Epitope Vaccine Candidate Against Streptococcus Suis Infections Using Immunoinformatics Approaches

O-acetyl-homoserine Sulfhydrylase Deficient Streptococcus Suis Serotype 2 Strain SC19 Becomes an Avirulent Strain and Provides Immune Protection Against Homotype Infection in Mice

Evaluation of immunogenicity and protective efficacy of recombinant outer membrane proteins of Haemophilus parasuis serovar 5 in a murine model

A Streptococcus suis Strain Δcps/ssna-msly (P353L)-SC19 Provides Cross-Protection against Serotypes 2 and 9 Strain Challenges in a Mouse Model

[Immunoprotective Effects of Helicobacter Pylori UreB and HpaA Bivalence Recombinant Vaccine with Inner Adjuvant on Experimental Infection in Mice].

Construction and Identification of a Recombinant Attenuated Salmonella Expressing Streptococcus suis sly Gene

A protein-based subunit vaccine with biological adjuvants provides effective protection against Pasteurella multocida in pigs

Peptidyl isomerase PrsA is surface-associated on Streptococcus suis and offers cross protection against serotype 9 strain.

Progress Toward the Development of a Vaccine Against Streptococcus suis Capsular Type 2

Recombinant SpaO and H1a as immunogens for protection of mice from lethal infection with Salmonella paratyphi A: implications for rational design of typhoid fever vaccines.

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

Both recombinant Bacillus subtilis Expressing PCV2d Cap protein and PCV2d-VLPs can stimulate strong protective immune responses in mice

Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination

Identification of the Immunogenic Outer Membrane Protein A Antigen of Haemophilus Parasuis by a Proteomics Approach and Passive Immunization with Monoclonal Antibodies in Mice

Enhanced Systemic and Mucosal Immune Responses to Haemophilus parasuis by Intranasal Administration of Lactic-Co-Glycolic Acid Microspheres

Evaluation of the immunogenicity and efficacy of a Hib polysaccharide-protein conjugate vaccine by using PsaA as carrier protein